MedTrace Logo

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

NCT04429191 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-06-11

No results posted yet for this study

Summary

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

Conditions

  • MYELODYSPLASTIC SYNDROME; MDS
  • ACUTE MYELOID LEUKEMIA; AML

Interventions

BIOLOGICAL

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Procedure: single intravenous infusion of JSP191 antibody

Sponsors & Collaborators

  • Jasper Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Lori Muffly, MD,MS · Stanford University

  • Andrew Artz, MD,MS · City of Hope Medical Center

  • Bart Scott, MD · Fred Hutchinson Cancer Center

  • Catherine Lee, MD · Huntsman Cancer Institute/ University of Utah

  • Arpita Gandhi, MD · Oregon Health and Science University

  • Ankur Varma, MD,PhD · Rush University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-08
Primary Completion
2023-10-15
Completion
2023-12-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04429191 on ClinicalTrials.gov